Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease - free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology